Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129961 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
A Phase 4 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
NCT00129961 is a Phase 4 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 86 participants.
The verdict
NCT00129961, a Phase 4 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.
Interventions
- DRUG sirolimus
- DRUG cyclosporine or tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129961
The ClinicalTrials.gov registry entry for NCT00129961 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sirolimus is the first listed.
NCT00129961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00129961 about?
NCT00129961 is a clinical study titled "Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients". The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.
What is the current status of trial NCT00129961?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2005-08. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00129961?
The interventions under investigation include: sirolimus (DRUG), cyclosporine or tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00129961?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.